Atherosclerosis 129 (1997) 281-283

## Author index

Volume 129 (1997)

Adams, M.R., R. McCredie, W. Jessup, J. Robinson, D. Sullivan, D.S. Celermajer, Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease 129, 261

Arima, N., see Miyamoto, T. 129, 207 Asayama, K., see Hayashibe, H. 129, 53 Ashby, J.P., see Wenham, P.R. 129, 185 Azakami, S., see Miyamoto, T. 129, 207

Bagga, M., see Millican, S.A. 129, 17
Barter, P., see Nestel, P. 129, 231
Bauer, P., see Neunteufl, T. 129, 111
Baum, K., see Kontush, A. 129, 119
Beisiegel, U., see Kontush, A. 129, 119
Bondjers, G., see Maxwell, S. 129, 89
Brayne, C.E., see Galinsky, D. 129, 177
Brunet, S., F. Guertin, L. Thibault, V. Gavino, E. Delvin, E. Levy, Iron-salicylate complex induces peroxidation, alters hepatic lipid profile and affects plasma lipoprotein composition 129, 159

Candlish, J.K., N. Saha, J.W. Mak, Plasma lipids and apolipoproteins in a population of Orang Asli ('aborigines') from West Malaysia 129, 49
Celermajer, D.S., see Adams, M.R. 129, 261
Clifton, P., see Nestel, P. 129, 231
Colquhoun, D., see Nestel, P. 129, 231
Cremer, P., D. Nagel, H. Mann, B. Labrot, R. Müller-Berninger, H. Elster, D. Seidel, Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study

(GRIPS). I. Risk factors for myocardial infarction in a

Delvin, E., see Brunet, S. 129, 159 Demacker, P.N.M., see Mol, M.J.T.M. 129, 169 Dening, T.R., see Galinsky, D. 129, 177 de Rijke, Y.B., see Mol, M.J.T.M. 129, 169 Dhall, D.P., see Shats, E.A. 129, 9

cohort of 5790 men 129, 221

Easton, D.F., see Galinsky, D. 129, 177
Eddy, R., see Millican, S.A. 129, 17
Edwards, R.J., see Powell, J.T. 129, 41
Ehnholm, C., see Ylitalo, K. 129, 271
Eliasson, B., N. Mero, M.-R. Taskinen, U. Smith, The insulin resistance syndrome and postprandial lipid intolerance in smokers 129, 79
Elster, H., see Cremer, P. 129, 221
Eto, M., see Saito, M. 129, 73

Finckh, B., see Kontush, A. 129, 119
Forster, B.A., P.D. Weinberg, Evans' blue dye abolishes endothelium-dependent relaxation of rabbit aortic rings 129, 129
Franks, P.J., see Powell, J.T. 129, 41

Galinsky, D., C. Tysoe, C.E. Brayne, D.F. Easton, F.A. Huppert, T.R. Dening, E.S. Paykel, D.C. Rubinsztein, Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity 129, 177

Fuse, T., see Igarashi, M. 129, 27

Guertin, F., see Brunet, S. 129, 159

Gavino, V., see Brunet, S. 129, 159
Glogar, D., see Neunteufl, T. 129, 111
Görög, P., Modified low density lipoprotein is a potent stimulus for smooth muscle cell outgrowth from rat aortic explant in vitro 129, 1
Greenhalgh, R.M., see Powell, J.T. 129, 41

Hamilton-Craig, I., see Nestel, P. 129, 231
Hassan, A., see Neunteufl, T. 129, 111
Hayashibe, H., K. Asayama, T. Nakane, N. Uchida, Y. Kawada, S. Nakazawa, Increased plasma cholesteryl ester transfer activity in obese children 129, 53

Healy, H., see Westhuyzen, J. 129, 199 Henderson, B.G., see Wenham, P.R. 129, 185 Hirano, T., see Yoshino, G. 129, 33 Holm, G., see Maxwell, S. 129, 89 Homma, Y., T. Kobayashi, H. Yamaguchi, H. Ozawa, H. Sakane, H. Nakamura, Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia 129, 241

Huber, K., see Kostner, K.M. 129, 103 Hunt, J.V., see Millican, S.A. 129, 17 Huppert, F.A., see Galinsky, D. 129, 177

Igarashi, M., Y. Takeda, S. Mori, K. Takahashi, T. Fuse, M. Yamamura, Y. Saito, Depolymerized holothurian gly-cosaminoglycan (DHG) prevents neointimal formation in balloon-injured rat carotid artery 129, 27
Ishikawa, Y., see Shimizu, H. 129, 193

Janus, E.D., see Tan, K.C.B. 129, 59 Jessup, W., see Adams, M.R. 129, 261

Kahri, J., see Tilly-Kiesi, M. 129, 249

Kato, S., see Miyamoto, T. 129, 207 Katzenschlager, R., see Neunteufl, T. 129, 111 Kawada, Y., see Hayashibe, H. 129, 53 Kazumi, T., see Yoshino, G. 129, 33 Kennedy, D.G., see Young, P.B. 129, 67 Kennedy, S., see Young, P.B. 129, 67 Klaar, U., see Neunteufl, T. 129, 111 Kobayashi, T., see Homma, Y. 129, 241 Kohlschütter, A., see Kontush, A. 129, 119

Kontush, A., A. Reich, K. Baum, T. Spranger, B. Finckh, A. Kohlschütter, U. Beisiegel, Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia 129, 119

Kostner, K.M., K. Huber, T. Stefenelli, H. Rinner, G. Maurer, Urinary apo(a) discriminates coronary artery disease patients from controls 129, 103

Labrot, B., see Cremer, P. 129, 221
Lahdenperä, S., see Tilly-Kiesi, M. 129, 249
Lam, K.S.L., see Tan, K.C.B. 129, 59
Lappi, M., see Tilly-Kiesi, M. 129, 249
Leake, D.S., Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions? 129, 149
Levy, E., see Brunet, S. 129, 159
Lingenhel, A., see Raal, F.J. 129, 97
Loughrey, C.M., see McEneny, J. 129, 215
Luotola, H., see Tilly-Kiesi, M. 129, 249

Maeda, E., see Yoshino, G. 129, 33 Makino, I., see Saito, M. 129, 73 Mak, J.W., see Candlish, J.K. 129, 49 Mann, H., see Cremer, P. 129, 221 Maurer, G., see Kostner, K.M. 129, 103 Maxwell, S., G. Holm, G. Bondjers, O. Wi

Maxwell, S., G. Holm, G. Bondjers, O. Wiklund, Comparison of antioxidant activity in lipoprotein fractions from insulindependent diabetics and healthy controls 129, 89

McCredie, R., see Adams, M.R. 129, 261
McEneny, J., C.M. Loughrey, P.T. McNamee, E.R. Trimble,
I.S. Young, Susceptibility of VLDL to oxidation in patients on regular haemodialysis 129, 215

Meri, S., see Ylitalo, K. 129, 271
Mero, N., see Eliasson, B. 129, 79
Millican, S.A., M. Bagga, R. Eddy, M.J. Mitchinson, J.V.
Hunt, Effect of glucose-mediated LDL oxidation on the

Hunt, Effect of glucose-mediated LDL oxidation on the P388D1 macrophage-like cell line 129, 17

Mitchinson, M.J., see Millican, S.A. 129, 17

McNamee, P.T., see McEneny, J. 129, 215

Miyamoto, T., Y. Sasaguri, T. Sasaguri, S. Azakami, H. Yasukawa, S. Kato, N. Arima, K. Sugama, M. Morimatsu, Expression of stem cell factor in human aortic endothelial and smooth muscle cells 129, 207

Mol, M.J.T.M., Y.B. de Rijke, P.N.M. Demacker, A.F.H. Stalenhoef, Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment 129, 169

Molloy, A.M., see Young, P.B. 129, 67 Morimatsu, M., see Miyamoto, T. 129, 207 Mori, S., see Igarashi, M. 129, 27 Müller-Berninger, R., see Cremer, P. 129, 221 Murata, Y., see Yoshino, G. 129, 33

Nagata, K., see Yoshino, G. 129, 33 Nagel, D., see Cremer, P. 129, 221 Nair, C.H., see Shats, E.A. 129, 9 Nakamura, H., see Homma, Y. 129, 241 Nakane, T., see Hayashibe, H. 129, 53 Nakazawa, S., see Hayashibe, H. 129, 53

Nestel, P., L. Simons, P. Barter, P. Clifton, D. Colquhoun, I. Hamilton-Craig, K. Sikaris, D. Sullivan, A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin 129, 231

Neunteufl, T., R. Katzenschlager, A. Hassan, U. Klaar, S. Schwarzacher, D. Glogar, P. Bauer, F. Weidinger, Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease 129, 111
Nuotio, I., see Ylitalo, K. 129, 271

Ozawa, H., see Homma, Y. 129, 241

Pagliero, F., see Schreier, L. 129, 127
Pajukanta, P., see Ylitalo, K. 129, 271
Paykel, E.S., see Galinsky, D. 129, 177
Peltonen, L., see Ylitalo, K. 129, 271
Penney, M.D., see Wenham, P.R. 129, 185
Pilcher, G., see Raal, F.J. 129, 97
Porkka, K.V.K., see Ylitalo, K. 129, 271

Poulter, N.R., see Powell, J.T. 129, 41

Powell, J.T., R.J. Edwards, P.C. Worrell, P.J. Franks, R.M. Greenhalgh, N.R. Poulter, Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study 129, 41

Puolakka, J., see Tilly-Kiesi, M. 129, 249 Pyörälä, T., see Tilly-Kiesi, M. 129, 249 Raal, F.J., G. Pilcher, D.C. Rubinsztein, A. Lingenhel, G. Utermann, Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects 129, 97

Rae, P.W.H., see Wenham, P.R. 129, 185 Reich, A., see Kontush, A. 129, 119 Rinner, H., see Kostner, K.M. 129, 103 Robinson, J., see Adams, M.R. 129, 261 Rubinsztein, D.C., see Galinsky, D. 129, 177 Rubinsztein, D.C., see Raal, F.J. 129, 97

Saha, N., see Candlish, J.K. 129, 49

Saito, M., M. Eto, I. Makino, Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesteryl ester synthesis in human macrophages 129, 73

Saito, Y., see Igarashi, M. 129, 27
Sakane, H., see Homma, Y. 129, 241
Saltissi, D., see Westhuyzen, J. 129, 199
Sanguinetti, S., see Schreier, L. 129, 127
Sasaguri, T., see Miyamoto, T. 129, 207
Sasaguri, Y., see Miyamoto, T. 129, 207

Schreier, L., F. Pagliero, S. Sanguinetti, R. Wikinski, Influence of the medium on the assessment of LDL resistance to oxidation: lag time in phosphate buffered saline is longer than in sodium chloride solution 129, 127

Schwarzacher, S., see Neunteufl, T. 129, 111

Scott, J.M., see Young, P.B. 129, 67 Seidel, D., see Cremer, P. 129, 221

Shats, E.A., C.H. Nair, D.P. Dhall, Interaction of endothelial cells and fibroblasts with modified fibrin networks: role in atherosclerosis 129, 9

Shimizu, H., T. Taniguchi, Y. Ishikawa, M. Yokoyama, Effects of nitric oxide on cholesterol metabolism in macrophages 129, 193

Shiu, S.W.M., see Tan, K.C.B. 129, 59
Sikaris, K., see Nestel, P. 129, 231
Simons, L., see Nestel, P. 129, 231
Smith, U., see Eliasson, B. 129, 79
Spranger, T., see Kontush, A. 129, 119
Stalenhoef, A.F.H., see Mol, M.J.T.M. 129, 169
Stefenelli, T., see Koster, K.M. 129, 103
Sugama, K., see Miyamoto, T. 129, 207
Sullivan, D., see Adams, M.R. 129, 261
Sullivan, D., see Nestel, P. 129, 231

Takahashi, K., see Igarashi, M. 129, 27 Takeda, Y., see Igarashi, M. 129, 27 Taniguchi, T., see Shimizu, H. 129, 193

Suurinkeroinen, L., see Ylitalo, K. 129, 271

Tan, K.C.B., S.W.M. Shiu, E.D. Janus, K.S.L. Lam, LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-1 129, 59

Taskinen, M.-R., see Tilly-Kiesi, M. 129, 249
Taskinen, M.-R., see Ylitalo, K. 129, 271
Thibault, L., see Brunet, S. 129, 159
Tilly-Kiesi, M., J. Kahri, T. Pyörälä, J. Puolakka, H. Luotola, M. Lappi, S. Lahdenperä, M.-R. Taskinen, Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen—progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women 129, 249

Trimble, E.R., see McEneny, J. 129, 215 Tysoe, C., see Galinsky, D. 129, 177

Taskinen, M.-R., see Eliasson, B. 129, 79

Uchida, N., see Hayashibe, H. 129, 53 Urayama, T., see Yoshino, G. 129, 33 Utermann, G., see Raal, F.J. 129, 97

Vakkilainen, J., see Ylitalo, K. 129, 271 Viikari, J.S.A., see Ylitalo, K. 129, 271

Walker, S.W., see Wenham, P.R. 129, 185
Weidinger, F., see Neunteufl, T. 129, 111
Weinberg, P.D., see Forster, B.A. 129, 129
Weir, D.G., see Young, P.B. 129, 67
Wenham, P.R., B.G. Henderson, M.D. Penney, J.P. Ashby,

Wenham, P.R., B.G. Henderson, M.D. Penney, J.P. Ashby, P.W.H. Rae, S.W. Walker, Familial ligand-defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK 129, 185

Westhuyzen, J., D. Saltissi, H. Healy, Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls 129, 199

Wikinski, R., see Schreier, L. **129**, 127 Wiklund, O., see Maxwell, S. **129**, 89 Worrell, P.C., see Powell, J.T. **129**, 41

Yamaguchi, H., see Homma, Y. 129, 241 Yamamura, M., see Igarashi, M. 129, 27 Yasukawa, H., see Miyamoto, T. 129, 207

Ylitalo, K., K.V.K. Porkka, S. Meri, I. Nuotio, L. Suurinkeroinen, J. Vakkilainen, P. Pajukanta, J.S.A. Viikari, L. Peltonen, C. Ehnholm, M.-R. Taskinen, Serum complement and familial combined hyperlipidemia 129, 271

Yokoyama, M., see Shimizu, H. 129, 193 Yoshiko Naka, see Yoshino, G. 129, 33

Yoshino, G., T. Hirano, E. Maeda, Y. Murata, Yoshiko Naka, K. Nagata, T. Kazumi, T. Urayama, Effect of longterm exogenous hyperinsulinemia and fructose or glucose supplementation on triglyceride turnover in rats 129, 33 Young, I.S., see McEneny, J. 129, 215

Young, P.B., S. Kennedy, A.M. Molloy, J.M. Scott, D.G. Weir, D.G. Kennedy, Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs 129, 67



Atherosclerosis 129 (1997) 284-285

## Subject index

Volume 129 (1997)

ACAT 129, 159 Acetylated LDL 129, 193 Acidic pH 129, 149 Acromegaly 129, 59 Acylation stimulating protein 129, 271 Adipsin-acylation stimulating protein 129, 271 Ageing 129, 177 Angiotensin converting enzyme 129, 177 Antioxidants 129, 89, 169 Apo C-I 129, 177 Apo E 129, 177 Apolipoprotein Al 129, 49 Apolipoprotein B-100 129, 185 Apolipoprotein B 129, 41, 49 Apolipoprotein E3/2 129, 73 Apolipoprotein E 129, 73 Apolipoproteins 129, 53 Atherosclerosis 129, 1, 17, 53, 89, 103, 119, 149, 169, 199, 207, 261

Bile acid sequestrant 129, 241 Brachial artery 129, 111

C3a-desArg 129, 271 Caeruloplasmin 129, 149 Carotid neointimal thickening 129, 27 CETP 129, 241 Child 129, 53 Cholesterol metabolism 129, 193 Cholesteryl ester synthesis 129, 73 Cholesteryl ester transfer protein 129, 53, 59 Cigarette smoking 129, 79 c-kit 129, 207 Combined hyperlipoproteinemia 129, 231 Complement system 129, 271 Conjugated diene formation 129, 215 Copper 129, 127, 149 Copper-induced lipid peroxidation 129, 215 Coronary artery disease 129, 111 Coronary heart disease 129, 119 Coronary risk factors 129, 221 Cytokines 129, 169

Depolymerized holothurian glycosaminoglycan 129, 27 Diabetes mellitus 129, 169

Endothelial cells 129, 9, 207
Endothelium 129, 111
Endothelium-dependent relaxation 129, 129
Enhanced chemiluminescence 129, 89
Evans blue dye 129, 129

Familial combined hyperlipidemia 129, 271
Familial defective apo B 100 129, 97
Familial hypercholesterolaemia 129, 97
Familial ligand-defective apolipoprotein B-100 129, 185
Fatty acids 129, 199
Fibrin network structure 129, 9
Fibroblasts 129, 9
Flow-mediated vasodilation 129, 111
Fractional catabolic rate 129, 33
Fructose 129, 33

Gemfibrozil **129**, 231 Glucose **129**, 17, 33 Growth hormone **129**, 59

HDL-cholesterol 129, 79
HDL subclasses 129, 249
Hemodialysis 129, 199
Hepatic lipase 129, 59
Heteroduplex analysis 129, 185
High-density lipoprotein 129, 89
Homocysteine 129, 67
Hypercholesterolemia 129, 185
Hyperlipidaemia 129, 119
Hyperlipoproteinemia 129, 241
Hypertriglyceridemia 129, 73

In situ hybridization 129, 207
Insulin-dependent diabetes mellitus 129, 89
Insulin-like growth factor-I 129, 59
Insulin resistance syndrome 129, 79
Iron 129, 149, 159

LCAT 129, 159, 241 LDL 129, 193 LDL cholesterol 129, 221 LDL oxidation 129, 169 LDL-particle size 129, 79 LDL-receptor 129, 241 Leukocytes 129, 261 Lipid hydroperoxides 129, 215 Lipid peroxidation 129, 67, 119, 199 Lipoprotein(a) 129, 97 Lipoprotein(A-I) 129, 249 Lipoprotein A-I 129, 79 Lipoprotein(A-I:A-II) 129, 249 Lipoprotein lipase 129, 59 Lipoproteins 129, 53, 79, 159, 199 Lipoprotein subfraction 129, 241 Liver disease 129, 119 Longevity 129, 177 Long-term hyperinsulinemia 129, 33 Low density lipoprotein 129, 149, 199 Low-density lipoprotein 129, 89 Low density lipoprotein 129, 17 Low density lipoproteins 129, 1 Low tar cigarettes 129, 41 Lysine 129, 199

Macrophage 129, 17, 73

Macrophages 129, 193

Malondialdehyde 129, 215

Medroxyprogesterone acetate 129, 249

Methylenetetrahydrofolate reductase 129, 177

Myocardial infarction 129, 221

Nitric oxide **129**, 129, 193, 261 Nitrous oxide **129**, 67 Norethisterone acetate **129**, 249

Obesity 129, 53
Orang Asli 129, 49
Oxidation 129, 17
Oxidized low density lipoprotein 129, 127, 149

Percutaneous transluminal coronary angioplasty
Peripheral atherosclerosis
Peroxidation 129, 159
Phosphate 129, 127
Pigs 129, 67
Plasma lipids 129, 49
Plasma Lp(a) 129, 103
Polymerase chain reaction 129, 185
Postprandial lipemia 129, 79
Predictors of response 129, 231
Prospective cohort study 129, 221

Rat 129, 27 Risk factor 129, 103 ROC-plot 129, 103 RT-PCR 129, 207

Salicylate 129, 159
Simvastatin 129, 231
Small dense low density lipoprotein 129, 59
Smoking 129, 41, 119, 169
Smooth muscle cell 129, 27
Smooth muscle cells 129, 1, 207
Statin therapy 129, 97
Stem cell factor 129, 207
Susceptibility to oxidation 129, 215
Systolic hypertension 129, 41

Transdermal 17 $\beta$ -estrogen 129, 249 Transferrin 129, 149 Triglyceride-rich lipoproteins 129, 73 Triton WR1339 129, 33 Trypan blue 129, 129

Ubiquinol-10 **129**, 119 Ultrasound **129**, 111

Vitamin B<sub>12</sub> **129**, 67 Vitamin E **129**, 89, 169